WHO Recommends GLP-1 Drugs as Obesity Treatment Tool in Adults
The World Health Organization (WHO) has marked a significant shift in its approach to obesity treatment by recommending GLP-1 drugs as a long-term management strategy for adults struggling with weight loss. The new guidelines, published in the medical journal JAMA, acknowledge that medication alone cannot tackle the global obesity burden and emphasize the need for a multi-faceted approach that incorporates healthy diets, physical activity, and counseling.
GLP-1 agonists, the class of medications being recommended, work by mimicking a hormone that signals to the brain when a person is full, thereby suppressing appetite. The drugs have gained popularity in recent years due to their potential in aiding weight loss and reducing the risk of obesity-related conditions such as high blood pressure, heart attacks, or strokes.
According to KFF, a nonprofit health think tank, 1 in 8 adults in the US are currently taking GLP-1 drugs for weight loss or other conditions like diabetes. WHO's new guidelines follow the approval of these medications by regulatory authorities such as the Food and Drug Administration and come at the request of member states.
The agency's recommendation is conditional, meaning that while the benefits likely outweigh the downsides, more evidence is needed to fully support their use. The need for lower prices to expand access to these life-changing medications has also been highlighted in the guidelines.
While the Trump administration recently announced a deal with pharmaceutical companies that could lower the cost of GLP-1 drugs for those who pay out-of-pocket or have Medicare or Medicaid, more work is needed to make these treatments accessible to all who need them. The WHO's new guidelines represent an important step towards recognizing the complex nature of obesity as a preventable and treatable chronic disease rather than just a lifestyle condition.
The World Health Organization (WHO) has marked a significant shift in its approach to obesity treatment by recommending GLP-1 drugs as a long-term management strategy for adults struggling with weight loss. The new guidelines, published in the medical journal JAMA, acknowledge that medication alone cannot tackle the global obesity burden and emphasize the need for a multi-faceted approach that incorporates healthy diets, physical activity, and counseling.
GLP-1 agonists, the class of medications being recommended, work by mimicking a hormone that signals to the brain when a person is full, thereby suppressing appetite. The drugs have gained popularity in recent years due to their potential in aiding weight loss and reducing the risk of obesity-related conditions such as high blood pressure, heart attacks, or strokes.
According to KFF, a nonprofit health think tank, 1 in 8 adults in the US are currently taking GLP-1 drugs for weight loss or other conditions like diabetes. WHO's new guidelines follow the approval of these medications by regulatory authorities such as the Food and Drug Administration and come at the request of member states.
The agency's recommendation is conditional, meaning that while the benefits likely outweigh the downsides, more evidence is needed to fully support their use. The need for lower prices to expand access to these life-changing medications has also been highlighted in the guidelines.
While the Trump administration recently announced a deal with pharmaceutical companies that could lower the cost of GLP-1 drugs for those who pay out-of-pocket or have Medicare or Medicaid, more work is needed to make these treatments accessible to all who need them. The WHO's new guidelines represent an important step towards recognizing the complex nature of obesity as a preventable and treatable chronic disease rather than just a lifestyle condition.